UK extends Covid-19 vaccination contract with Wockhardt

Our Bureau Mumbai | Updated on February 10, 2021

The contract period has been extended from 18 months to 24 months now — up to August 2022

Drugmaker Wockhardt has received a six-month extension of its contract with the government of the United Kingdom to “fill-finish” Covid-19 vaccines.

This expands the Mumbai-based company’s original agreement from 18 to 24 months, up to August 2022. And manufacturing will continue to be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales, it said.

Also read: Cyber-attacks, fire and now a suspicious package: the strange case of Covid-19 vaccine-linked companies

The UK plant had recently witnessed an untoward incident and had to be evacuated temporarily after a suspicious package was found on the premises.

On the extension of the vaccine contract, UK International Trade Secretary Liz Truss said on her visit to Mumbai, that the agreement would bring investment to the local area, besides jobs and security to the community during the pandemic.

Business Secretary Kwasi Kwarteng added that the UK was taking steps to ensure the manufacture of vaccines into 2022, “should we need to revaccinate or provide boosters to the population.”

“By extending our contract with Wockhardt, we will ensure the UK has uninterrupted fill and finish capacity, guaranteeing we have sufficient supplies to protect the British public in the long term,” Kwarteng said.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 10, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.